Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fredun Pharmaceuticals's interest expense for the
three
months ended in Mar. 2026 was ₹ -145 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-393 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Fredun Pharmaceuticals Interest Expense Historical Data
* Premium members only.
The historical data trend for Fredun Pharmaceuticals's Interest Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-393 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fredun Pharmaceuticals (BOM:539730) has a Interest Expense of ₹-393 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Fredun Pharmaceuticals and its competitors.
Is Fredun Pharmaceuticals' Interest Expense too high?
Fredun Pharmaceuticals' current Interest Expense is ₹-393 Mil. Overall, Fredun Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fredun Pharmaceuticals' Interest Expense compare to ZTS?
Fredun Pharmaceuticals' Interest Expense of ₹-393 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Fredun Pharmaceuticals and its competitors. Fredun Pharmaceuticals's current Interest Expense is ₹-393 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fredun Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fredun Pharmaceuticals (BOM:539730) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹534.52, compared to a current price of ₹903.85 — trading 69.1% above its estimated fair value. The current Interest Expense is ₹-393 Mil. Fredun Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Fredun Pharmaceuticals (BOM:539730), the current Interest Expense is ₹-393 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fredun Pharmaceuticals (BOM:539730) Overvalued in 2026?
Based on GuruFocus' analysis, Fredun Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹903.85 is trading 69.1% above its estimated GF Value™ of ₹534.52.
GuruFocus considers Fredun Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:539730:
Interest Expense: ₹-393 Mil
GF Value™: ₹534.52 vs. price of ₹903.85 (69.1% above fair value)
No single metric tells the full story. See the BOM:539730 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fredun Pharmaceuticals Ltd in its Endeavour to move ahead has now ventured into manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with Animal Healthcare products also with products ranging from allopathic formulations to on field diagnostic kits, Company's main objective is to be a holistic healthcare provider. The group is dedicated to improving lives of people. The Company operates only in a single segment i.e. Pharmaceutical Segment. The company has presence in Domestic as well as International market. The company generates majority of revenue from Domestic market.
67GF Score
Get the complete analysis for BOM:539730
Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539730 has been successfully added to your 
